Using two experimental anti-malarial vaccines, which work in different ways, can greatly reduce the number of malaria infections in animal studies.
Experimental vaccines, which independently achieve 48% and 68% reductions in malaria cases, can achieve 91% reduction when combined.
Presently, each vaccine is at a different stage of human trials, and there have not been efforts to combine them. However, a team led by Imperial College London have now tested the effectiveness when using the two types of vaccine together.
Reaching a potential 91% reduction in cases would have a huge impact on public health because the vaccines could be effective in areas where malaria is more prevalent.Dr Andrew Blagborough
The study, published today in the journal eLife, used genetically altered mouse parasites that express proteins expressed on the human version of the malaria parasite. The research was funded by the PATH’s Malaria Vaccine Initiative and the Medical Research Council (MRC), including researchers at Imperial’s MRC Centre for Outbreak Analysis and Modelling.
Lead researcher Dr Andrew Blagborough, from the Department of Life Sciences at Imperial, said: “This is the first direct evidence than combining vaccines of different types significantly improves their efficacy in terms of reducing malarial burden.
“Reaching a potential 91% reduction in cases would have a huge impact on public health because the vaccines could be effective in areas where malaria is more prevalent.”
Two types of vaccines
Malaria is caused by a group of parasites that have a complex life cycle, spending time in the mosquito midgut and salivary glands, in the human liver, and circulating in human blood, where they cause the disease.
The team tested two types of vaccines: those that prevent mosquitoes from transferring the parasites, called transmission-blocking vaccines (TBVs), and those that prevent the parasite from infecting the liver, termed pre-erythrocytic vaccines (PEVs).
RTS,S is the world’s first PEV malaria vaccine that has been shown to provide partial protection against malaria in young children by blocking infection of the liver. However, its maximum efficacy is under 50% (i.e. it reduces cases by around 50%).
There are currently several types of transmission-blocking vaccines in early trials, which are thought to reduce the number of parasites in the mosquito salivary glands. Their efficacy typically ranges from around 50-95%.
It has been assumed that combining these vaccines would increase their efficacy, but it has never been tested until now. The team found that when a partially effective PEV was combined with the most effective transmission-blocking vaccine, the efficacy was around 91%.
The team also found that combining any of the two types of vaccines improved efficacy of the mixture more than might be expected from the single efficacy of each vaccine separately.
Working towards elimination
Dr Morven Roberts, Programme Manager for parasites and neglected tropical diseases at the MRC, said: “While these findings are in the preliminary stages, they’re valuable as they shed light on optimising strategies for preventing malaria. Learning that combining vaccines can dramatically boost efficacy in mice provides another potential tactic for controlling this disease. This is timely research as global health officials work towards WHO targets to eliminate malaria by 2030.”
The team will next study how combined vaccines could work in more complex situations. Dr Blagborough said: “In the real world, the vaccine coverage we can achieve– how many people we can give it to – is important, as are the local levels of transmission, and how prevalent malaria currently is in that area.
“We plan to use a combination of rodent experiments and computer modelling to help us estimate effectiveness requirements for future vaccines.”
The efficacy of current lead malaria vaccines is known to reduce over time after vaccines are administered, so the team will also investigate how combined vaccines perform in the long term.
The Latest on: Malaria
via Google News
The Latest on: Malaria
- Growing malaria drug resistance worldwide threatens to be ‘disastrous’ on March 18, 2019 at 8:31 am
It’s not clear why, but the Greater Mekong Subregion—Cambodia, southern China, Laos, Myanmar, Thailand, and Vietnam—is a major source of malaria drug resistance. Each time a drug has been ... […]
- Spotlight: Experts warn malaria for cancer treatment "scientifically unsound," risky for patients on March 18, 2019 at 7:27 am
LOS ANGELES, March 18 (Xinhua) -- Medical experts have warned of the dangers of using malaria treatment for cancer, and called the "malariotherapy" lack of scientific basis and risky for patients. A ... […]
- Guided STED nanoscopy enables super-resolution imaging of blood stage malaria parasites on March 18, 2019 at 6:04 am
Malaria remains a global threat, with 216 million cases world-wide and over 400,000 deaths in 2016 alone 1. There are six parasite species from the genus Plasmodium causing malaria in humans: P. ... […]
- Health Dept plays down concerns over malaria outbreak in SA on March 18, 2019 at 1:59 am
Despite experts warning that there may be a rise in cases because of a lack of urgency in dealing with cases, the department said that it is working with countries in the region to ensure there isn’t ... […]
- Increase in cases of malaria on March 18, 2019 at 1:46 am
Malaria is on the rise in South Africa because of the lack of urgency in dealing with the silent killer, experts warn. According to Goodbye Malaria, an NGO that aims to eliminate malaria in Africa, ... […]
- Prevent Malaria by Keeping Your Home Mosquito-Free Naturally With These Tips on March 15, 2019 at 3:56 am
Malaria and other mosquito-borne diseases like dengue are widespread across the world. If proper and timely treatment is not carried out, these can also turn out to be life-threatening. It’s because ... […]
- Mosquito-killing drug offers new tool for fighting malaria on March 14, 2019 at 10:01 am
DAKAR (Thomson Reuters Foundation) - A mosquito-killing drug tested in Burkina Faso reduced malaria cases by a fifth among children and could be an important new tool in the global fight against the ... […]
- Mosquito-killing drug reduced malaria episodes by a fifth among children, according to randomised trial on March 14, 2019 at 1:22 am
First evidence that repeated mass administration of ivermectin can reduce malaria incidence in children aged five or younger without an increase in adverse events for the wider population given ... […]
- BOHEMIA will develop a new vector control strategy to kill malaria-transmitting mosquitoes on March 13, 2019 at 11:50 pm
Global efforts to fight malaria have hit a plateau and new tools that complement those currently in use are needed to achieve global malaria goals. In this context, the Barcelona Institute for Global ... […]
via Bing News